ATS Statements by Microbiology, Tuberculosis and Pulmonary Infections Assembly
- Update: Fatal and Severe Liver Injuries Associated With Rifampin and Pyrazinamide for Latent Tuberculosis Infection, and Revisions in American Thoracic Society/ CDC Recommendations-United States, 2001
- An Official ATS Workshop Summary: Recent Advances and Future Directions in Pneumocystis Pneumonia (PCP)
- IDSA/ATS Community Acquired Pneumonia Guidelines
- ATS/IDSA Statement: Diagnosis, Prevention and Treatment of Nontuberculous Mycobacterial Diseases
- Hepatotoxicity of Antituberculosis Therapy
- ATS-CDC-IDSA: Controlling Tuberculosis in the United States
- Guidelines for the Management of Adults with Community-acquired Pneumonia
- Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia
- Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection
- Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria
- Rapid Diagnostic Test for Tuberculosis: What is the Appropriate Use?
- ATS/CDC/IDSA Statement: Treatment of Tuberculosis
- Treatment of Tuberculosis and Tuberculosis Infection in Adults & Children
